◆ NeutralBFRI
Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026
GlobeNewswire Inc.·
Biofrontera Inc. (NASDAQ: BFRI) announced it will report third quarter 2026 financial results on November 13, 2026, followed by a management conference call. The company, a biopharmaceutical firm focused on dermatological treatments using photodynamic therapy, recently received FDA approval in September 2026 for Ameluz® Red Light PDT to treat superficial basal cell carcinoma, marking the first and only photodynamic therapy approved in the U.S. for skin cancer treatment.
Read Full Article at GlobeNewswire Inc. →